Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Monofer versus oral iron sulphate in IBD-related iron deficiency anaemia
2009-012544-16Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Jul 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) and inflammatory bowel disease (IBD) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Change in haemoglobin from baseline to week 8. Started Jul 2009; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2009-012544-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012544-16.